Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults

19Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To compare hospital mortality in patients with aspiration-associated pneumonia treated with ceftriaxone (CTRX) and in those treated with ampicillin/sulbactam (ABPC/SBT). Methods: From a Japanese multicentre observational study cohort of patients with pneumonia, those diagnosed with pneumonia and having at least one aspiration-related risk factor were selected. Propensity score-matching analysis was used to balance baseline characteristics of the participants and compare hospital mortality of patients treated with CTRX and those treated with ABPC/SBT. Results: Hospital mortality did not significantly differ between patients treated with CTRX and those treated with ABPC/SBT (6.6 vs 10.7%, risk difference -4.0, 95% CI [-9.4, 1.3]; p = 0.143). Conclusion: Further studies are needed to compare CTRX and ABPC/SBT treatments in patients with aspiration-associated pneumonia.

Cite

CITATION STYLE

APA

Hasegawa, S., Shiraishi, A., Yaegashi, M., Hosokawa, N., Morimoto, K., & Mori, T. (2019). Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults. Journal of Comparative Effectiveness Research, 8(15), 1275–1284. https://doi.org/10.2217/cer-2019-0041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free